Read the receipt.
- Displayed amount
- $299 /30 days
- Delivery route
- Oral
- Product status
- FDA-approved medicine
- Membership in this figure
- See provider inclusions and terms
- Quantity
- 30-day supply
- Upfront commitment
- Confirm the initial charge and billing period
Confirm taxes, diagnostics and any costs not specified in the quote.
Sources: Lilly — Foundayo self-pay and savings terms, FDA — Foundayo approval, April 1, 2026
What this price means.
Foundayo is an approved non-peptide GLP-1 medicine, not semaglutide and not a generic version of another GLP-1. The selected strength and offer window determine this price. Preserve the expiry or refill condition in a budget; the medicine-only figure does not establish an all-inclusive care plan.
Sources: Lilly — Foundayo self-pay and savings terms, FDA — Foundayo approval, April 1, 2026
The product context.
FDA approved Foundayo (orforglipron) on April 1, 2026 for certain adults with obesity or overweight with a weight-related condition, alongside diet and physical activity. Orforglipron is a non-peptide small molecule; we include it as a related GLP-1 option. Approval of Foundayo does not confer approval on a compounded version.
Sources: FDA — Foundayo approval, April 1, 2026, Lilly — Foundayo self-pay and savings terms
Before you pay.
What will actually be charged today?
Confirm the initial charge and billing period. Request the full amount due today, its supply period, the next charge date and the renewal amount. The displayed price is a sourced offer, not a personalized invoice.
Is this a clinical recommendation?
No. This review covers public product and price information. Eligibility, treatment choice and the prescribed amount require an appropriate clinician. We have not tested this product.
What should I compare it with?
Start with the same ingredient, route, supplied quantity and billing term. Add any separate care or membership fees. Differences in product approval or formulation remain meaningful even when prices are similar.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Lilly — Foundayo self-pay and savings terms ↗
Official public information; price and terms checked October 8, 2026.
Checked October 8, 2026
- FDA — Foundayo approval, April 1, 2026 ↗
Approval and indicated population; a non-peptide GLP-1 medicine.
Checked October 8, 2026